2TZ.STU Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
- Market cap
- EUR 1.79B
- P/E
- 16.6x
- P/B
- 2.22x
- ROE
- 21.7%
- Dividend yield
- 26.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2TZ.STU undervalued?
Graham number2TZ.STU trades 27.9% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited fundamental analysis
No fundamental analysis for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited yet.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved…
Full company profileTianjin Zhong Xin Pharmaceutical Group Corporation Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.18B | 5.69B | 6.36B | 6.99B | 6.60B | 6.91B | 8.25B | 8.22B | 7.31B | 4.92B | 4.91B |
| Gross Profit | 2.00B | 2.21B | 2.64B | 2.95B | 2.58B | 2.76B | 3.29B | 3.62B | 3.52B | 3.64B | 3.73B |
| Operating Income | 313M | 357M | 476M | 566M | 596M | 613M | 723M | 868M | 855M | 971M | 1.51B |
| EBITDA | - | 613M | 728M | 846M | 879M | 991M | 1.11B | 1.26B | 2.74B | 2.61B | 1.52B |
| Net Income | 422M | 476M | 562M | 626M | 662M | 769M | 862M | 987M | 2.23B | 2.13B | 1.29B |
| EPS | - | 0.62 | 0.73 | 0.81 | 0.86 | 0.99 | 1.11 | 2.47 | 2.89 | 5.33 | 1.67 |
| Balance Sheet | |||||||||||
| Total Assets | 6.36B | 6.62B | 7.11B | 7.84B | 8.28B | 9.07B | 10.2B | 10.2B | 10.8B | 11.7B | 10.5B |
| Total Liabilities | 2.06B | 2.00B | 2.05B | 2.32B | 2.33B | 2.55B | 3.61B | 3.58B | 2.92B | 4.59B | 4.59B |
| Shareholders' Equity | 4.14B | 4.48B | 4.93B | 5.39B | 5.81B | 6.36B | 6.52B | 6.60B | 7.84B | 7.10B | 5.94B |
| Cash & Short-term Investments | 1.15B | 992M | 1.47B | 1.48B | 1.99B | 2.28B | 2.88B | 2.13B | 2.94B | 1.02B | 2.45B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 418M | -3.97M | 350M | 495M | 671M | 852M | 677M | 688M | 925M | 461M | - |
| Capital Expenditure | 116M | 114M | 176M | 206M | 189M | 157M | 108M | 141M | 118M | 119M | 70.8M |
| Free Cash Flow | - | -118M | 174M | 290M | 482M | 695M | 569M | 548M | 807M | 342M | 1.59B |
| Ratios | |||||||||||
| ROE | 10.2% | 10.6% | 11.4% | 11.6% | 11.4% | 12.1% | 13.2% | 14.9% | 28.4% | 30.0% | 21.7% |
| ROA | 6.6% | 7.2% | 7.9% | 8.0% | 8.0% | 8.5% | 8.5% | 9.6% | 20.7% | 18.2% | 12.2% |
| Net Profit Margin | 6.8% | 8.4% | 8.8% | 8.9% | 10.0% | 11.1% | 10.4% | 12.0% | 30.5% | 43.3% | 26.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited dividends
- Dividend yield
- 26.04%
- Forward dividend
- 0.60 EUR
- Payout ratio
- 46.0%
- Ex-dividend date
- Jun 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 981M | 2.45 | 46.0% |
| 2024 | CNY 1.01B | 1.31 | 45.3% |
| 2023 | CNY 877M | 2.19 | 88.9% |
| 2022 | CNY 387M | 0.50 | 45.0% |
| 2021 | CNY 232M | 0.30 | 30.2% |
| 2020 | CNY 233M | 0.30 | 35.2% |
| 2019 | EUR 173M | 0.23 | 27.7% |
| 2018 | EUR 165M | 0.21 | 29.3% |
| 2017 | EUR 127M | 0.17 | 26.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
- Insiders 9.16%
- Institutions 0.13%
- Public & others 90.71%
- Shares outstanding 200M
- Free float 426M
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited company profile
- Company name
- Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
- Ticker
- 2TZ.STU
- ISIN
- CNE100000924
- Exchange
- Stuttgart Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,619
- Fiscal year end
- December
- Address
- No. 17, Baidi Road, Tianjin, China, 300193
- Phone
- 86 22 2702 0892
- Website
- jydrt.com.cn
About Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and preparations, and nutritional supplements. In addition, the company is involved in pharmaceutical and drug retail business. Further, it offers Suxiao Jiuxin pills, Qingyan drop pills, Jingwanhong ointment, Angong Niuhuang pills, Qingfei pills, anti-inflammatory pills, Qinggong Shoutao pills, Biqi capsules, Niuhuang Qingxin pills, Tongmai Yangxin pills, and Weichang An pills. Additionally, the company pharmaceutical logistic services. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1981 and is based in Tianjin, the People's Republic of China.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited management
9- Ms. Lei WangChairman of the Board · born 1971
- Mr. Jian MaChief Financial Officer · born 1978
- Mr. Hong ZhouDeputy GM, Chief Engineer & Executive Director · born 1970
- Mr. Min GuoExecutive Director · born 1971
- Mr. Yu ZhangChief Manufacturing Officer · born 1973
- Mr. Mingjie ShangEmployee Director · born 1969
- Ms. Yan JiaoSecretary to the Board of Directors · born 1977
- Tang ChaoAccounting Supervisor
- Mr. Hong ChenExecutive Vice President · born 1971